CPT® Code 90385

1. Indications

The Rho(D) immune globulin (RhIg) is indicated for specific clinical situations where passive immunity is necessary to prevent Rh sensitization. The following conditions warrant the use of this immunizing agent:

• Prevention of Rh Sensitization in Rh-negative mothers who are carrying an Rh-positive fetus to avoid hemolytic disease of the newborn.
• Postpartum Administration to Rh-negative mothers after the delivery of an Rh-positive infant to prevent the development of antibodies against Rh-positive blood cells.
• Management of Miscarriages or Abortions in Rh-negative women to prevent sensitization following fetal blood exposure.
• Trauma or Procedures that may lead to fetal-maternal hemorrhage, such as amniocentesis or chorionic villus sampling, in Rh-negative women.

2. Procedure

The administration of Rho(D) immune globulin involves several key procedural steps to ensure safety and efficacy. The following steps outline the process:

• Step 1: Patient Identification - Confirm the patient's Rh status through blood typing to ensure that the individual is Rh-negative and requires the administration of RhIg.
• Step 2: Preparation of the Product - Retrieve the appropriate mini-dose of Rho(D) immune globulin (CPT® Code 90385) from storage, ensuring that it is within the expiration date and has been stored correctly according to manufacturer guidelines.
• Step 3: Administration - Administer the RhIg intramuscularly, typically in the deltoid muscle or the anterolateral thigh, using aseptic technique to minimize the risk of infection. The injection site should be prepared with an appropriate antiseptic solution.
• Step 4: Monitoring - After administration, monitor the patient for any immediate adverse reactions, such as allergic responses or injection site reactions, and provide appropriate post-injection care.

3. Post-Procedure

Following the administration of Rho(D) immune globulin, patients should be observed for a short period to ensure there are no immediate adverse effects. It is important to provide the patient with information regarding potential side effects, which may include mild fever, soreness at the injection site, or allergic reactions. Patients should also be advised to report any unusual symptoms following the injection. Documentation of the administration, including the dose, site of injection, and any reactions observed, should be completed in the patient's medical record. Additionally, follow-up appointments may be necessary to monitor the patient's Rh status and overall health, particularly in the context of pregnancy and postpartum care.